Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia
 

The U.S. Food and Drug Administration today approved Sicor Biotech's tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

More...